DefinitionThis section has been translated automatically.
An antiretrovirally active CCR5 core receptor antagonist for the treatment of HIV infection. The active substance attacks a human target structure and not, as with the other antiretrovirally active substances, key enzymes of the HIV virus. The aim of the active substance is to prevent HIV viruses from entering their host cells (see entry inhibitors below).
Pharmacodynamics (Effect)This section has been translated automatically.
Cave! Maraviroc is only effective against a certain form of the HI viruses, the CCR5-tropical or R5 viruses. Other strains enter the cell by other routes.
You might also be interested in
IndicationThis section has been translated automatically.
Pretreated adult patients with exclusively CCR5 tropical HIV strains. Cave! Do not use on CXCR4 tropical or dual tropical HIV strains. Only to be used in combination therapy with other antiretroviral agents.
Dosage and method of useThis section has been translated automatically.
2 times/day 150-600 mg p.o.
Undesirable effectsThis section has been translated automatically.
Very common: diarrhea, nausea and headaches. Frequently: Increase of transaminases, weight loss. Dizziness, paresthesia, impaired sense of taste (dysesthesia), drowsiness, chesty cough, drug exanthema.
ContraindicationThis section has been translated automatically.
Hypersensitivity to peanuts or soya.
PreparationsThis section has been translated automatically.
Celsentri
Note(s)This section has been translated automatically.
Remember! Before prescribing Maraviroc, a tropism test must always be carried out!
- Cave! For Aplaviroc, another HIV entry inhibitor, the approval studies were stopped due to possible liver toxicity. With the CCR5-inhibitor Vicriviroc, an increased incidence of lymphomas has been described.
- Caution! Patients treated with Maraviroc are significantly more sensitive to West Nile virus infections.
Prof. Dr. med. Peter Altmeyer